Abstract
Dopamine receptors have been identified in a number of organs and tissues, which include the central and peripheral nervous systems, various vascular beds, the heart, the gastrointestinal tract, and the kidney. Dopamine receptors are classified into D1- and D2-like subtypes based on their structure and pharmacology; during conditions of moderate sodium balance, more than 50% of renal sodium excretion is regulated by D1-like receptors. Most of the knowledge on the actions of dopamine has been focused on the D1 dopamine receptor. The D5 dopamine receptor also belongs to the D1-like receptor subfamily. Disruption of the D5 receptor results in hypertension. However, unlike the D1 receptor, the hypertension in D5 receptor null mice is caused by the increased activity of the sympathetic nervous system, apparently due to activation of oxytocin, V1 vasopressin, and non-NMDA receptors in the central nervous system. In this paper, we review the physiological action of D5 receptor on the central and peripheral nervous systems, and discuss the possible mechanisms by which hypertension develops when the D5 receptor function is perturbed.
Keywords: Essential hypertension, dopamine receptor, sympathetic nervous system, sodium excretion, vasorelaxation
Related Journals
Related eBooks
Related Articles
-
Aldosterone to Renin Ratio (ARR) in Clinical use, with Reference to the Primary Care Setting: ARR to Whom, When, How, What for?
Current Hypertension Reviews Epoxyeicosatrienoic Acids as a Therapeutic Target for Nephropathy Associated with Diabetes and Hypertension
Current Hypertension Reviews Aldosterone and Resistant Hypertension
Current Hypertension Reviews Nitric Oxide and Arginine Dysregulation: A Novel Pathway to Pulmonary Hypertension in Hemolytic Disorders
Current Molecular Medicine The Promise of Plant-Derived Substances as Inhibitors of Arginase
Mini-Reviews in Medicinal Chemistry Modulation of Renin-Angiotensin System and Arterial Stiffness: Evidence from Clinical Trials
Current Hypertension Reviews Central Nervous System Circuitry and Peripheral Neural Sympathetic Activity Responsible for Essential Hypertension
Current Neurovascular Research Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome
Current Pharmaceutical Design Atherosclerosis - New Targets and Therapeutics
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Gene-Gene and Gene-Environment Interplay Represent Specific Susceptibility for Different Types of Ischaemic Stroke and Leukoaraiosis
Current Medicinal Chemistry Sorbitane Monostearate and Cholesterol based Niosomes for Oral Delivery of Telmisartan
Current Drug Delivery Gene Patents in the Primary Prevention of Vascular Diseases
Recent Patents on DNA & Gene Sequences (DIscontinued) Effect of Oral Alkali Supplementation on Progression of Chronic Kidney Disease
Current Hypertension Reviews New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is)
Current Medicinal Chemistry Old and New Gasotransmitters in the Cardiovascular System: Focus on the Role of Nitric Oxide and Hydrogen Sulfide in Endothelial Cells and Cardiomyocytes
Current Pharmaceutical Biotechnology The Impact of Hypertension as a Road to Heart Failure with Preserved Ejection Fraction: Diagnostic Value of Two-Dimensional Speckle Tracking Echocardiography for the Early Impairment of Left Atrial-Left Ventricular-Arterial Coupling
Current Hypertension Reviews Hypertensive Disorders in Pregnancy Current Practice Review
Current Hypertension Reviews A Single Pill to Treat Postmenopausal Hypertension? Not Yet
Current Topics in Medicinal Chemistry Essential Hypertension: Translating Pathophysiology into Pharmacogenomics
Current Pharmacogenomics TA-65, A Telomerase Activator improves Cardiovascular Markers in Patients with Metabolic Syndrome
Current Pharmaceutical Design